Filing Flows › Energy › Arcadia Biosciences (RKDA)
Arcadia Biosciences (RKDA) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Arcadia Biosciences (RKDA) Q2 2026 earnings results →
Q2 2026 Revenue down 1% year over year to $1.4M · 434¢ of every $1 of revenue lost · operating margin -34.4%
Arcadia Biosciences made $1.4M in Q2 2026 (-0.8% Y/Y). Operating margin -34.4%, net loss $6.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.4M in Q2 2026, down 1% year over year and up 31% from the previous quarter.
Operating costs exceeded revenue by $496K, an operating margin of -34.4%. Total costs fell 1% while revenue fell 1%. The quarter ended with a net loss of $6.3M, wider than the previous quarter's $4.4M loss. Net interest and other expense of $5.8M was the main reason.
Operating cash flow was −$319K. Non-cash charges added back $14K of share-based compensation. Working capital and other items added $5.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $1.4M | -0.8% | -34.4% | −$6.3M | −$319K |
| Q1 2026 | 10-Q | May 14, 2026 | $1.1M | -8% | -70.8% | −$4.4M | −$1.1M |
| Q4 2025 | 10-K | Mar 26, 2026 | $901K | -26% | -152.6% | −$1.3M | −$822K |
| Q3 2025 | 10-Q | Nov 7, 2025 | $1.3M | -15% | -88.5% | $856K | −$257K |
| Q2 2025 | 10-Q | Aug 14, 2025 | $1.5M | +11% | -34.4% | −$4.5M | −$2.0M |
| Q1 2025 | 10-Q | May 8, 2025 | $1.2M | +22% | 44.2% | $2.6M | −$1.6M |
| Q4 2024 | 10-K | Mar 25, 2025 | $1.2M | +56% | -187.4% | −$4.1M | −$2.2M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Arcadia Biosciences
Arcadia has leveraged its history as a leader in science-based approaches to develop high value products and drive innovation in the consumer goods industry. Since acquiring the assets of Zola in May 2021, Arcadia has provided consumers with a way to rehydrate, reset, and reenergize with Zola coconut water products. Previously, Arcadia developed products, primarily in wheat, which it commercialized through the sale of food products, trait licensing and royalty agreements. On May 14, 2024, Arcadia sold its non-GMO Resistant Starch (“RS”) durum wheat trait to longtime partner Corteva Agriscience (“Corteva”) for total cash consideration of $4.0 million. Refer to Note 11 to the consolidated financial statements for further details of the transaction.
In its own words, from its 10-K, filed Mar 26, 2026.
Arcadia Biosciences against its Crude Petroleum & Natural Gas peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -0.8% against the peers' median +46%. Operating margin: -34.4% against the peers' median 19.5%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| RKDA Arcadia Biosciences | Q2 2026 | $1.4M | -0.8% | -34.4% |
| EOG EOG Resources | Q3 2026 | $8.5B | +46% | 41.9% |
| OXY Occidental Petroleum | Q2 2026 | $8.1B | +53% | 48.5% |
| DVN Devon Energy | Q3 2026 | $6.9B | +58% | 18.3% |
| FANG Diamondback Energy | Q3 2026 | $5.4B | +38% | 46.0% |
| EXE Expand Energy | Q3 2026 | $3.3B | +11% | 19.5% |
| PARR PAR Pacific Holdings | Q3 2026 | $3.1B | +52% | 15.5% |
| OVV Ovintiv | Q3 2026 | $2.6B | +26% | 33.7% |
| SM SM Energy | Q3 2026 | $2.2B | +167% | 10.9% |
Source: Arcadia Biosciences 10-Q on SEC EDGAR · CIK 1469443 · Crude Petroleum & Natural Gas
13F: who owns RKDA and who is buying
More on RKDA
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results